SFE Investment Counsel Has $2.28 Million Stake in Pfizer Inc. (NYSE:PFE)

SFE Investment Counsel lowered its stake in shares of Pfizer Inc. (NYSE:PFE) by 37.8% in the fourth quarter, Holdings Channel.com reports. The firm owned 79,104 shares of the biopharmaceutical company’s stock after selling 48,165 shares during the period. SFE Investment Counsel’s holdings in Pfizer were worth $2,277,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Worth Asset Management LLC purchased a new position in shares of Pfizer in the 1st quarter worth approximately $29,000. Briaud Financial Planning Inc purchased a new position in Pfizer in the third quarter valued at approximately $30,000. Sanctuary Wealth Management L.L.C. purchased a new position in Pfizer in the fourth quarter valued at approximately $50,000. Mizuho Securities Co. Ltd. purchased a new position in Pfizer in the third quarter valued at approximately $34,000. Finally, VisionPoint Advisory Group LLC lifted its stake in Pfizer by 52,350.0% in the third quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 1,047 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Stock Down 0.4 %

Shares of PFE traded down $0.09 during mid-day trading on Thursday, reaching $25.33. 26,574,240 shares of the stock traded hands, compared to its average volume of 42,343,496. The firm has a market cap of $143.43 billion, a price-to-earnings ratio of 70.25, a P/E/G ratio of 1.16 and a beta of 0.61. The stock has a fifty day simple moving average of $27.19 and a 200 day simple moving average of $28.76. Pfizer Inc. has a 12-month low of $25.23 and a 12-month high of $40.56. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.69.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.29. The firm had revenue of $14.25 billion during the quarter, compared to the consensus estimate of $14.37 billion. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The firm’s revenue was down 41.3% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.14 earnings per share. Sell-side analysts expect that Pfizer Inc. will post 2.24 EPS for the current fiscal year.

Analysts Set New Price Targets

PFE has been the topic of a number of analyst reports. Guggenheim initiated coverage on shares of Pfizer in a report on Friday, February 23rd. They set a “buy” rating and a $36.00 target price on the stock. TD Cowen cut shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price on the stock. in a report on Thursday, January 4th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a report on Monday. Finally, Argus cut shares of Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Twelve analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $36.88.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.